Showing results (831-840 of 1,075) with videos related to

Sort By:
Pageof 108
Circulation|January 12, 2011
Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosisCorrado Tamburino, Davide Capodanno, Angelo Ramondo, et al.
JACC. Cardiovascular Imaging|April 20, 2015
Eroded Versus Ruptured Plaques at the Culprit Site of STEMI: In Vivo Pathophysiological Features and Response to Primary PCIFrancesco Saia, Kenichi Komukai, Davide Capodanno, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|January 20, 2023
Determinants and long-term outcomes of largely uncovered struts in thin-struts drug-eluting stents assessed by optical coherence tomographyFrancesco Moretti, Chiara Bernelli, Dario Pellegrini, et al.
Journal of the American College of Cardiology|July 18, 2015
Revisiting Sex Equality With Transcatheter Aortic Valve Replacement Outcomes: A Collaborative, Patient-Level Meta-Analysis of 11,310 PatientsStephen A O'Connor, Marie-Claude Morice, Martine Gilard, et al.
Thrombosis and Haemostasis|November 27, 2015
Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient dataJean-Luc Reny, Pierre Fontana, Willibald Hochholzer, et al.
European Heart Journal|January 30, 2020
Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromesRobert F Storey, Paul A Gurbel, Jurrien Ten Berg, et al.
Circulation. Cardiovascular Interventions|June 1, 2012
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trialRobert C Welsh, Sunil V Rao, Uwe Zeymer, et al.
The Heart Surgery Forum|April 30, 2013
Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgeryMichael S Firstenberg, Cornelius M Dyke, Dominick J Angiolillo, et al.
NEJM Evidence|February 6, 2024
Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent SurgeryDeepak L Bhatt, Charles V Pollack, C David Mazer, et al.
American Heart Journal|December 24, 2018
The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarctionC Michael Gibson, Mathieu Kerneis, Megan K Yee, et al.
Pageof 108